Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5214538 | Tetrahedron | 2015 | 6 Pages |
Hepatocellular carcinoma is one of the most common kind of cancers in clinical, and its clinical treatment is quite difficult. The latest research suggests that pyridazinone with a novel molecular skeleton shows excellent activity against hepatocellular carcinoma in vitro and in vivo. Considering YHHU-759 as the leading compound for reasonable structure modification, a series of 3,3â²-bipyridazine derivatives including 8 novel compounds in this study were designed, synthesized and screened for their anti-hepatoma activities against liver cancer cell lines SMMC-7721, BEL-7402 and QGY-7703 in vitro. The result shows that all of the 3,3â²-bipyridazine derivatives have good anti-hepatoma activities.
Graphical abstractDownload high-res image (112KB)Download full-size image